Heilmann, Emmanuel http://orcid.org/0000-0001-8148-9490
Costacurta, Francesco
Geley, Stephan http://orcid.org/0000-0002-3169-5322
Mogadashi, Seyad Arad
Volland, Andre
Rupp, Bernhard
Harris, Reuben Stewart http://orcid.org/0000-0002-9034-9112
von Laer, Dorothee http://orcid.org/0000-0001-5825-7237
Funding for this research was provided by:
Austrian Science Fund (ATU57495534)
Article History
Received: 18 August 2021
Accepted: 15 March 2022
First Online: 27 April 2022
Competing interests
: D.v.L. is founder of ViraTherapeutics GmbH. D.v.L serves as a scientific advisor to Boehringer Ingelheim and Pharma KG. E.H. and D.v.L have received an Austrian Science Fund (FWF) grant in the special call “SARS urgent funding”. RSH is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight University Professor, and an Investigator of the Howard Hughes Medical Institute. All other authors declare no competing interests.